News

From 19 December 2025, new prescriptions for GnRH analogues for the purpose of puberty suppression for children or adolescents with gender incongruence or gender dysphoria will no longer be permitted for patients who have not been prescribed a GnRH analogue previously.   This follows Government regulations introduced on 17 November 2025. The new regulations are published online here: Medicines (Restriction on Prescribing Gonadotropin-releasing Hormone Analogues) Amendment Regulations 2025  ...

Kia ora   The December 2025 edition of Prescriber Update  is now available on the Medsafe website. Please can you share it with your networks.   Kind regards   Medsafe Pharmacovigilance Team

Pharmac is seeking feedback on a proposal to fund a new strength of thiamine hydrochloride injection: 50 mg per ml in a 2 ml ampoule. Pharmac currently funds two strengths of thiamine hydrochloride injection: 100 mg per ml (1 ml and 2 ml vials) 125 mg per ml (2 ml vial) These would continue to be funded alongside the proposed 50 mg per ml (2 ml ampoule). If approved, this new strength would be funded from 1 April 2026.  Proposal to fund a new strength of thiamine hydrochloride injection   We...

New listing: We are writing to inform you of a brand change for lanreotide inj 60 mg per 0.5 ml, 0.5 ml syringe (Mytolac). Due to a supply issue with the Mytolac brand we have an alternate brand funded and available.   Key messages: lanreotide inj 60 mg per 0.5 ml, 0.5 ml syringe ( Mytolac ) brand is in short supply due to manufacturing delays. Alternative   Mytolac Section 29 product was listed (funded) 1 July 2025. Mytolac S29 - The outer box is in English with Mytolac  as the brand....

​

​